NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00173-0130-93 | 00173-0130 | Melphalan Hydrochloride | Alkeran | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 16, 1993 | May 31, 2012 | No Longer Used | |
64144-0503-01 | 64144-0503 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 13, 2016 | In Use | |
64144-0501-01 | 64144-0501 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 13, 2016 | In Use | |
63759-3001-01 | 63759-3001 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec 31, 2016 | In Use | |
72237-0101-01 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jul 10, 2019 | In Use | |
63020-0536-30 | 63020-0536 | ponatinib hydrochloride | Iclusig | 10.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 11, 2021 | In Use | |
63020-0040-90 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sep 15, 2021 | In Use | |
70771-1058-02 | 70771-1058 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb 9, 2017 | In Use | |
00378-0005-85 | 00378-0005 | Everolimus | Everolimus | 2.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2021 | In Use | |
00085-1425-01 | 00085-1425 | Temozolomide | Temodar | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | Oct 22, 2014 | In Use |
00002-3977-60 | 00002-3977 | Selpercatinib | RETEVMO | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | May 8, 2020 | In Use | |
62856-0720-30 | 62856-0720 | Lenvatinib | Lenvima | 10.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Feb 13, 2015 | In Use | |
63323-0104-05 | 63323-0104 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Jul 18, 2001 | In Use | |
00003-0852-22 | 00003-0852 | Dasatinib | Sprycel | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2008 | In Use | |
63323-0142-12 | 63323-0142 | Ifosfamide | Ifosfamide | 1.0 g/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 28, 2003 | In Use | |
65162-0806-51 | 65162-0806 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 3, 2015 | In Use | |
51808-0119-01 | 51808-0119 | I 131 Mini | I 131 Mini | 500.0 mCi/1 | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | May 23, 2012 | In Use | |
00085-1519-03 | 00085-1519 | Temozolomide | Temodar | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | In Use | |
62559-0920-51 | 62559-0920 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 16, 2020 | In Use | |
00078-0874-21 | 00078-0874 | Ribociclib | Kisqali | 200.0 mg/1, 200.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Mar 13, 2017 | In Use | |
00078-0670-66 | 00078-0670 | Pazopanib Hydrochloride | Votrient | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, Lck, FMS | Oral | Jul 12, 2016 | Oct 31, 2024 | In Use |
00078-0566-51 | 00078-0566 | Everolimus | Afinitor | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 31, 2009 | In Use | |
66758-0047-03 | 66758-0047 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 31, 2010 | Jul 19, 2015 | In Use |
62756-0023-43 | 62756-0023 | Topotecan Hydrochloride | Topotecan hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sep 2, 2015 | Sep 30, 2015 | No Longer Used |
68382-0245-05 | 68382-0245 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use |
Found 11120 results — Export these results